Extended Data Fig. 10 | Non-redundant roles for PLA2G2D and PD-1. ( a ) Experimental outline of mouse DC-mediated allogeneic T cell activation to study the effect of PLA2G2D–Fc. DCs and T cells were derived from different mouse strains. ( b ) IFNγ secretion (MSD immunoassay) in culture supernatant (set-up as in a ) after exposure to control Fc or PLA2G2D–Fc or proteins in the absence or presence of anti-PD-1 antibodies (n = 4 per group). ( c ) IFNγ secretion (MSD immunoassay) after allogeneic DC-mediated T cell activation using DCs derived from Pla2g2d +/+ or Pla2g2d −/− mice (set-up as in a , n = 4 per group). ( d ) IFNγ production (MSD immunoassay) from pembrolizumab (anti-PD-1)- treated allogeneic human monocyte-derived DC and T cell co-cultures using normally differentiated DCs exposed to PLA2G2D–Fc or control Fc proteins as well as anti-PLA2G2D antibodies (clone 47.M2) during the allogeneic culture (n = 2–3 per group). ( e ) IFNγ production (MSD immunoassay) from pembrolizumab-treated allogeneic human monocyte-derived DC and T cell co-cultures using mature DCs differentiated in the presence of PLA2G2D, H47Q PLA2G2D, or Fc control proteins (n = 3 per group. ( f ) Tumour growth curves depicting tumour volume (mm 3 ) in humanized- PLA2G2D C57BL/6 mice (n = 12 per group) following inoculation with MC38 tumour cells and treatment with isotype control, anti-PLA2G2D (44.H1), anti-PD-1, or anti-PLA2G2D and anti-PD-1 antibodies. ( g , h ) Individual tumour growth curves for the experiments shown in Fig. 5h,i. Data are presented as mean ± s.e.m. ( b – f ). P values were calculated using an unpaired t-test ( b , c , e ) or a two-way ANOVA with Fisher’s LSD ( d , f ). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Exact P values in Supplementary Data).